Desmopressin stimulation testing: Response to intravenous and intranasal forms

Area of Science:

• Hematology
• Pediatric Medicine
• Pharmacology

Background:

• Desmopressin (DDAVP) is a synthetic analog of vasopressin used to manage bleeding in mucocutaneous bleeding disorders.
• Available in intravenous and intranasal formulations, individual responses to DDAVP can vary, necessitating a test dose.
• Limited comparative trials exist for intranasal versus intravenous DDAVP efficacy.

Purpose of the Study:

• To compare the efficacy of intravenous and intranasal desmopressin in pediatric patients with von Willebrand disease (VWD) or probable VWD.
• To assess if both formulations yield comparable responses in laboratory assays.

Main Methods:

• Retrospective analysis of medical records for 58 pediatric patients undergoing desmopressin stimulation testing.
• Data collection included demographic information and hematologic assays pre- and post-desmopressin administration.
• Assays measured von Willebrand antigen, Ristocetin Cofactor, and Factor VIII levels.

Main Results:

• Both intravenous and intranasal desmopressin administration resulted in increased von Willebrand antigen, Ristocetin Cofactor, and Factor VIII levels.
• The increase in von Willebrand antigen was significantly greater with intravenous administration compared to intranasal.
• Both formulations demonstrated a positive response, indicating potential therapeutic benefit.

Conclusions:

• Intravenous and intranasal desmopressin are effective in desmopressin stimulation testing for pediatric patients with VWD.
• Both formulations can identify patients who will respond positively to desmopressin therapy.
• While both are effective, intravenous desmopressin may elicit a more pronounced increase in von Willebrand antigen.